Angiotensin II (medication)

Last updated

Angiotensin II
Angiotensin II.svg
Clinical data
Trade names Giapreza
Other namesAng II
AHFS/Drugs.com Monograph
License data
Routes of
administration 		Intravenous injection
Drug class Vasoconstrictor
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding None
Metabolism Proteolysis by glutamyl aminopeptidase, angiotensin converting enzyme 2
Metabolites Angiotensin III, angiotensin-(1-7)
Elimination half-life Less than one minute (IV administration)
Identifiers
  • L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C50H71N13O12
Molar mass 1046.197 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
  • InChI=InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1
  • Key:CZGUSIXMZVURDU-JZXHSEFVSA-N

Angiotensin II, sold under the brand name Giapreza, is a medication that is used to treat hypotension resulting from septic shock or other distributive shock. It is a synthetic vasoconstrictor peptide that is identical to human hormone angiotensin II. [3] The Food and Drug Administration approved the use of angiotensin II in December 2017 to treat low blood pressure resulting from septic shock. [4]

Contents

The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [5] It is approved as a generic medication. [6]

Medical uses

Angiotensin II is a vasoconstrictor used to increase blood pressure in adults with septic or other distributive shock. [1] Angiotensin II is a naturally occurring hormone secreted as part of the renin-angiotensin system that results in powerful systemic vasoconstriction. [7] [8] The vasopressor effects of angiotensin have been studied since it was first isolated in the late 1930s. [9]

Adverse effects

Angiotensin II treated patients are at an increased risk of thromboembolic events. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received angiotensin II compared to placebo treated patients in the ATHOS-3 study [13% (21/163 patients) vs. 5% (8/158 patients)]. [10] It is recommended that patients be on concurrent venous thromboembolism prophylaxis. Other adverse reactions include thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia. [1]

Angiotensin II acts on angiotensin receptor (AT1) on presynaptic adrenergic nerves → release of catecholamine → excessive catecholamine can be harmful as it can cause myocyte necrosis. [11]

References

  1. 1 2 3 "Giapreza- angiotensin ii injection". DailyMed. 20 June 2020. Retrieved 17 September 2020.
  2. ↑ "Giapreza EPAR". European Medicines Agency. 23 August 2019. Retrieved 13 June 2024.
  3. ↑ Kaufman MB (March 2018). "Pharmaceutical Approval Update". P & T. 43 (3): 141–170. PMC   5821238 . PMID   29491694.
  4. ↑ "FDA approves drug to treat dangerously low blood pressure" (Press release). U.S. Food and Drug Administration (FDA). 21 December 2017. Archived from the original on 7 March 2024.
  5. ↑ New Drug Therapy Approvals 2017. U.S. Food and Drug Administration (FDA) (Report). January 2018. Archived from the original (PDF) on 14 September 2019. Retrieved 16 September 2020.
  6. ↑ "Generic Giapreza Availability". Drugs.com. 10 September 2025. Retrieved 3 October 2025.
  7. ↑ Brown SM, Lanspa MJ, Jones JP, Kuttler KG, Li Y, Carlson R, et al. (March 2013). "Survival after shock requiring high-dose vasopressor therapy". Chest. 143 (3): 664–671. doi:10.1378/chest.12-1106. PMC   3590882 . PMID   22911566.
  8. ↑ Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, et al. (October 2014). "Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study". Critical Care. 18 (5): 534. doi: 10.1186/s13054-014-0534-9 . PMC   4212099 . PMID   25286986.
  9. ↑ Bradley SE, Parker B (November 1941). "The Hemodynamic Effects of Angiotonin in Normal Man". The Journal of Clinical Investigation. 20 (6): 715–719. doi:10.1172/JCI101265. PMC   435102 . PMID   16694877.
  10. ↑ Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. (August 2017). "Angiotensin II for the Treatment of Vasodilatory Shock". The New England Journal of Medicine. 377 (5): 419–430. doi: 10.1056/NEJMoa1704154 . hdl: 1959.13/1353018 . PMID   28528561. S2CID   205102054.
  11. ↑ Liaudet L, Calderari B, Pacher P (November 2014). "Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity" (PDF). Heart Failure Reviews. 19 (6): 815–824. doi:10.1007/s10741-014-9418-y. PMID   24398587. S2CID   22420796.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.